NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Revlimid® (lenalidomide): New important advice regarding viral reactivation

User Rating: 4 / 5

Star ActiveStar ActiveStar ActiveStar ActiveStar Inactive
 

Date: 13 April 2017

 

Description:

Cases of viral reactivation have been reported following treatment with lenalidomide, particularly in patients previously infected with the varicella zoster or hepatitis B viruses (HBV). Some cases of HBV reactivation progressed to acute hepatic failure and resulted in death. As such, hepatitis B virus status should be established before initiating treatment with lenalidomide and a physician with expertise in the treatment of hepatitis B should be consulted for patients who test positive for HBV infection. For previously infected patients, they should be closely monitored for signs and symptoms of viral reactivation, including active HBV infection, throughout therapy. Please refer to the Direct Healthcare Professional Communication (DHPC) issued by Celgene Sdn. Bhd. in agreement with NPRA for further information.

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Thursday 10 October 2024, 16:28:58.

Search

Main Menu English